Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Carya Ovata Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of Shagbark Hickory pollen allergies. It belongs to the class of pollen allergenic extracts used in subcutaneous immunotherapy.
Name
Carya Ovata Pollen
Raw Name
CARYA OVATA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
15
Variant Count
17
Last Verified
February 17, 2026
About Carya Ovata Pollen
Carya Ovata Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of Shagbark Hickory pollen allergies. It belongs to the class of pollen allergenic extracts used in subcutaneous immunotherapy.
Detailed information about Carya Ovata Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Carya Ovata Pollen.
Carya Ovata Pollen, commonly known as Shagbark Hickory pollen, is a biological substance used in the field of allergy and immunology. It is classified as a Non-Standardized Pollen Allergenic Extract [EPC]. This extract is derived from the pollen of the Carya ovata tree, a member of the Juglandaceae (walnut) family, which is native to the Eastern United States and parts of Canada. In clinical practice, this extract is utilized for two primary purposes: the diagnosis of allergic sensitivity through skin testing and the treatment of allergic disease through allergen immunotherapy (also known as 'allergy shots').
As a non-standardized extract, Carya Ovata Pollen does not have a federally mandated potency unit (such as the Bioequivalent Allergy Unit or BAU used for grasses or ragweed). Instead, its potency is typically expressed in Protein Nitrogen Units (PNU) or as a Weight/Volume (W/V) ratio. This means that while the manufacturing process is strictly controlled, the specific biological activity may vary slightly between manufacturers compared to standardized extracts. The FDA has regulated these extracts for decades, ensuring they meet rigorous safety and purity standards under the Public Health Service Act.
The mechanism of action for Carya Ovata Pollen depends on whether it is being used for diagnosis or treatment. When used for diagnostic skin testing, a small amount of the extract is introduced into the skin (epicutaneous or intradermal). In a sensitized individual, the Carya Ovata allergens bind to specific Immunoglobulin E (IgE) antibodies that are already attached to the surface of mast cells in the skin. This binding causes the mast cells to degranulate, releasing inflammatory mediators like histamine. This results in a localized 'wheal and flare' reaction (a raised bump and surrounding redness), confirming the patient's sensitivity to Shagbark Hickory pollen.
When used for Allergen Immunotherapy (AIT), the mechanism is much more complex and involves 're-training' the immune system. The goal is to induce immunological tolerance. This process occurs through several pathways:
Because Carya Ovata Pollen is a biological extract administered locally (subcutaneously or epicutaneously), it does not follow the traditional pharmacokinetic pathways of oral drugs (absorption, distribution, metabolism, and excretion).
Carya Ovata Pollen extracts are FDA-approved for the following indications:
Carya Ovata Pollen is available in the following dosage forms:
> Important: Only your healthcare provider can determine if Carya Ovata Pollen is right for your specific condition. Immunotherapy should only be administered by clinicians trained in the management of anaphylaxis.
Dosage for Carya Ovata Pollen is highly individualized and must be determined by an allergist based on the patient's sensitivity levels. There is no 'standard' dose, but rather a dosing schedule divided into two phases:
Patients typically receive injections once or twice weekly. The starting dose is usually a very dilute concentration (e.g., 0.05 mL of a 1:100,000 W/V or 1:10,000 W/V dilution). The volume is gradually increased (e.g., 0.1, 0.2, 0.3, 0.5 mL) until the patient reaches the next concentration level. This continues until the 'Maintenance Dose' is achieved.
Once the maximum tolerated dose is reached, the frequency of injections is decreased to once every 2 to 4 weeks. A common maintenance dose is 0.5 mL of the most concentrated vial (e.g., 1:20 W/V or 10,000-20,000 PNU/mL), though this varies significantly by patient tolerance.
Carya Ovata Pollen is approved for use in children who demonstrate significant allergic sensitivity. The dosing logic is identical to that of adults; however, healthcare providers may use smaller volume increments during the build-up phase to ensure safety. There is no specific age cutoff, but immunotherapy is rarely started in children under the age of 5 due to the requirement for cooperation with injections and the ability to communicate symptoms of a systemic reaction.
No dosage adjustments are required for patients with renal impairment, as the extract is not cleared through the kidneys in a manner that affects systemic toxicity.
No dosage adjustments are required for patients with hepatic impairment.
While no specific dose reduction is mandated, elderly patients should be screened for underlying cardiovascular disease. The use of Carya Ovata Pollen may be riskier in seniors who cannot tolerate the physiological stress of a systemic reaction or the use of epinephrine (the primary treatment for anaphylaxis).
If a dose is missed during the build-up phase, the next dose may need to be reduced depending on how much time has passed.
An 'overdose' in the context of immunotherapy refers to receiving a dose higher than the patient's current tolerance level. This can occur due to a dosing error or a sudden increase in environmental pollen exposure (priming).
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients undergoing immunotherapy with Carya Ovata Pollen will experience local reactions. These are generally considered a normal part of the immune response.
> Warning: Stop taking Carya Ovata Pollen and call your doctor immediately if you experience any of these.
There are no known long-term 'toxic' side effects of Carya Ovata Pollen, as it is a natural protein. However, long-term immunotherapy can lead to:
Carya Ovata Pollen, like all allergenic extracts, carries a significant risk of Anaphylaxis.
Report any unusual symptoms to your healthcare provider.
Carya Ovata Pollen is not a conventional medication; it is a potent biological agent. The most critical safety factor is the 30-minute observation rule. Patients must never leave the clinic early, as the majority of life-threatening reactions occur within this timeframe. Additionally, patients should avoid vigorous exercise for 2-4 hours after an injection, as increased blood flow can speed up the absorption of the allergen, increasing the risk of a systemic reaction.
No FDA black box warnings for Carya Ovata Pollen. (Note: While allergenic extracts as a class carry severe warnings regarding anaphylaxis in their package inserts, they do not always utilize the specific 'Black Box' format used for synthetic drugs; however, the warnings regarding anaphylaxis are treated with the same level of clinical gravity).
Carya Ovata Pollen does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive until they have been fully cleared by a medical professional. Some patients experience post-injection fatigue, which may impair concentration.
While there is no direct chemical interaction, alcohol consumption can cause vasodilation (widening of blood vessels). This could theoretically increase the rate of allergen absorption from the injection site. It is recommended to avoid alcohol for several hours after an injection.
Immunotherapy is usually a 3-to-5-year commitment. Stopping early may result in the return of allergy symptoms. There is no 'withdrawal' syndrome associated with stopping Carya Ovata Pollen, but the patient will lose the immunological protection they have built up.
> Important: Discuss all your medical conditions with your healthcare provider before starting Carya Ovata Pollen.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Patients allergic to Carya Ovata (Shagbark Hickory) often show cross-reactivity with other members of the Juglandaceae family. This includes:
A patient who is highly sensitive to one of these may react more strongly to the Carya Ovata extract.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Carya Ovata Pollen.
Carya Ovata Pollen is classified as Pregnancy Category C.
It is not known whether the allergenic components of Carya Ovata Pollen are excreted in human milk. However, because these are large proteins that are processed locally, it is highly unlikely that they would reach the infant in significant amounts. Breastfeeding is generally considered safe during immunotherapy, but the mother should be monitored for systemic reactions which could indirectly affect the infant.
As discussed in the dosage section, Carya Ovata Pollen is safe and effective for children, typically aged 5 and older. Studies have shown that early intervention with immunotherapy in children with allergic rhinitis can prevent the subsequent development of asthma (the 'Allergic March'). Parents must be educated on how to recognize signs of a reaction in children, such as sudden coughing, stomach pain, or behavioral changes.
Patients over age 65 may be at higher risk for complications. The primary concern is the presence of underlying coronary artery disease or hypertension. If a senior requires epinephrine for a reaction, it could trigger a cardiac event. The decision to use Carya Ovata Pollen in the elderly must be based on the severity of the allergy versus the cardiovascular risk profile.
No specific studies have been conducted in patients with renal impairment. However, given the local processing and proteolysis of the extract, renal function does not play a role in the safety or efficacy of the treatment. No dose adjustments are necessary.
Similar to renal impairment, hepatic function does not affect the metabolism of allergenic proteins. No dose adjustments are required for patients with liver disease.
> Important: Special populations require individualized medical assessment.
Carya Ovata Pollen acts as an immunomodulator. At the molecular level, the extract contains specific proteins (allergens) that are captured by dendritic cells. These cells present the allergen peptides to naive T-cells. In an allergic person, this usually results in Th2 cell activation. Immunotherapy forces the production of IL-10 producing Regulatory T-cells. These Tregs suppress the allergic cascade. Furthermore, B-cells are signaled to switch production from IgE to IgG4, which acts as a protective 'sink' for the pollen allergens before they can reach mast cells.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Local) |
| Protein Binding | N/A |
| Half-life | Hours (for protein fragments) |
| Tmax | 30-60 minutes (for local absorption) |
| Metabolism | Proteolysis (Cellular) |
| Excretion | Cellular clearance |
Carya Ovata Pollen is a member of the Allergenic Extracts class. It is specifically a Non-Standardized Pollen Extract. Related medications include other tree pollen extracts (Oak, Maple, Birch) and standardized extracts like Short Ragweed or Timothy Grass.
Common questions about Carya Ovata Pollen
Carya Ovata Pollen extract is primarily used for the diagnosis and treatment of allergies to Shagbark Hickory trees. In a clinical setting, an allergist uses a small amount of the extract for skin testing to see if a patient develops a localized allergic reaction. If a significant allergy is confirmed, the extract is then used in 'allergy shots,' also known as immunotherapy. This involves giving the patient gradually increasing doses of the pollen to help their immune system become less sensitive over time. It is highly effective for reducing symptoms of hay fever and allergic asthma triggered by hickory trees.
The most common side effects are localized to the site where the injection was given. These include redness, itching, and swelling, which can range from the size of a mosquito bite to several centimeters in diameter. Some patients also report feeling tired or having a mild headache for a few hours after their appointment. These reactions are usually temporary and can be managed with over-the-counter antihistamines or cold compresses. However, any large or painful swelling should be reported to your doctor before your next dose.
It is generally advised to avoid alcohol for several hours before and after receiving an injection of Carya Ovata Pollen. Alcohol causes blood vessels to dilate (widen), which could theoretically cause the pollen extract to be absorbed into your system more quickly than intended. This rapid absorption could increase the risk of a systemic allergic reaction or make a mild reaction more severe. Additionally, alcohol can mask the early symptoms of an allergic reaction, such as flushing or a rapid heartbeat. Always consult your allergist for their specific policy on alcohol use during treatment.
Carya Ovata Pollen is generally not started during pregnancy because of the risk of anaphylaxis, which can be dangerous for both the mother and the developing fetus. However, if a woman is already on a stable maintenance dose and is tolerating the injections well, most allergists will continue the treatment at that same dose. The dosage is almost never increased during pregnancy to avoid the risk of a new reaction. If you are planning to become pregnant or find out you are pregnant while on allergy shots, it is vital to inform your healthcare provider immediately. They will perform a risk-benefit analysis based on your specific medical history.
Immunotherapy with Carya Ovata Pollen is a long-term process and does not provide immediate relief like an antihistamine pill. Most patients begin to notice a decrease in their allergy symptoms after 3 to 6 months of consistent treatment, which usually coincides with reaching the maintenance dose. The full benefits are typically realized after one to two years of therapy. To achieve long-lasting or permanent relief, a full course of 3 to 5 years is generally recommended. Skipping doses or stopping early can significantly delay or reduce the effectiveness of the treatment.
Yes, you can stop taking Carya Ovata Pollen injections at any time without experiencing physical withdrawal symptoms. Unlike some medications that require tapering, allergenic extracts do not cause a chemical dependency. However, stopping the treatment before the recommended 3-to-5-year mark often means that your allergy symptoms will eventually return. The 'tolerance' your immune system has built up may fade over several months. If you are considering stopping because of side effects or scheduling issues, talk to your doctor first, as they may be able to adjust your dose instead.
If you miss a dose, you should contact your allergist's office as soon as possible to reschedule. The protocol for a missed dose depends on how long it has been since your last injection and whether you are in the 'build-up' or 'maintenance' phase. If you are only a few days late, your doctor may give you the usual dose. If you have missed several weeks, your doctor will likely need to reduce your dose significantly to ensure safety and then gradually build you back up. Never try to 'double up' on a dose to make up for a missed one.
There is no clinical evidence to suggest that Carya Ovata Pollen extracts cause weight gain. The extract consists of natural proteins and a small amount of preservative, and it does not contain hormones or steroids which are typically associated with weight changes. If you experience weight gain while on immunotherapy, it is likely due to other factors such as lifestyle changes, other medications (like oral steroids used for asthma), or an unrelated medical condition. You should discuss any concerns about weight with your primary care physician.
Carya Ovata Pollen can be taken alongside most standard medications, but there are critical exceptions. You must inform your doctor if you are taking beta-blockers (often used for blood pressure or heart issues), as these can make it difficult to treat a severe allergic reaction. ACE inhibitors and certain antidepressants may also interact with how your body handles a reaction. Most allergy medications, like nasal sprays and antihistamines, are fine to continue, although you may need to stop antihistamines briefly before skin testing. Always provide a full list of your medications to your allergist.
Allergenic extracts like Carya Ovata Pollen are biological products rather than simple chemical drugs, so the term 'generic' is not used in the same way. However, several different biological manufacturers produce Shagbark Hickory pollen extracts. While they all contain the same basic pollen proteins, they are not considered 'interchangeable' like generic Ibuprofen. If you switch to a different manufacturer's extract, your doctor will usually reduce your dose slightly to account for potential differences in potency. This is a standard safety precaution in the field of allergy.